CD8A and neoplasm: Statistics of CD8/FoxP3 ratio in tumor tissue showed that the infiltration rate of CD8+ T cells was increased after the combination of osimertinib and bevacizumab, while the infiltration rate of FoxP3+ T cells was decreased (Figure 5(g)).